Stocklytics Platform
Asset logo for symbol BHVN
Biohaven Pharmaceutical Holding Co Ltd
BHVN49
$21.15arrow_drop_up8.56%$1.75
Asset logo for symbol BHVN
BHVN49

$21.15

arrow_drop_up8.56%
Key Stats
Open$20.96
Prev. Close$20.55
EPS-9.37
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range20.09
21.82
52 Week Range16.20
62.21
Ratios
Revenue-
EBITDA Margin %-
EPS-9.37
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

BHVN-
US Healthcare Sector-
US Market-
check_circle

BHVN / Market

BHVN exceeded the US Market which returned 2.57% over the last twenty four hours.
check_circle

BHVN / Healthcare Sector

BHVN exceeded the US Healthcare sector which returned 3.48% over the last twenty four hours.

Biohaven Pharmaceutical Holding Co Ltd (BHVN) Statistics

Biohaven Pharmaceutical Holding Co Ltd (BHVN) is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for neurological diseases. The company's portfolio includes several product candidates that have the potential to address the unmet medical needs of patients suffering from conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and spinocerebellar ataxia (SCA). BHVN is committed to improving patients' lives through the development of novel treatments that target the underlying causes of these diseases.
With a market capitalization of over $4 billion, BHVN is considered a mid-cap stock in the pharmaceutical sector. The company's valuation metrics indicate that it is currently trading at a price-to-earnings ratio of 44.81, indicating that investors are willing to pay a premium for the company's future earnings potential. BHVN's price-to-sales ratio is 281.44, suggesting that the company's revenue per share is relatively high compared to its stock price. This could be indicative of a strong market demand for the company's products.
add Biohaven Pharmaceutical Holding Co Ltd to watchlist

Keep an eye on Biohaven Pharmaceutical Holding Co Ltd

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock's performance compared to its sector and the market over the past year?

Over the past year, Biohaven Pharmaceutical Holding Co Ltd (BHVN) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 20.77%, Biohaven Pharmaceutical Holding Co Ltd has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 36.14%, it has fallen short of the market average. This comparison highlights Biohaven Pharmaceutical Holding Co Ltd's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock?

The PE ratio for Biohaven Pharmaceutical Holding Co Ltd (BHVN) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock?

The Earnings Per Share (EPS) for Biohaven Pharmaceutical Holding Co Ltd (BHVN), calculated on a diluted basis, is -$9.37. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock?

The operating margin for Biohaven Pharmaceutical Holding Co Ltd (BHVN) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Biohaven Pharmaceutical Holding Co Ltd (BHVN) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Biohaven Pharmaceutical Holding Co Ltd (BHVN) is -$841.6M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Biohaven Pharmaceutical Holding Co Ltd (BHVN) have?

Biohaven Pharmaceutical Holding Co Ltd (BHVN) has a total debt of $28.99M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$55.4M.

Take Your Investments to a Whole New Level